COVID-19 roundup: FDA’s expanded access program for convalescent plasma; plus more funding from BARDA, tests from Eurofins, BD-BioGx, and more
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BARDA’s latest push into plasma-based COVID-19 therapies includes an expanded access program for convalescent plasma and funding for Emergent’s hyperimmune program. To combat the pandemic, a pair of companies began rolling out tests, while GSK and Innovax partnered on vaccine development.
FDA on Friday named the Mayo Clinic as the lead institution for the program, developed with funding from HHS’s Biomedical Advanced Research and Development Authority (BARDA), which aims to provide patients access to convalescent plasma. The American Red Cross will help collect plasma from those who have recovered form COVID-19 and distribute the plasma to patients. Other participating institutions include Johns Hopkins University, Washington University, Einstein Medical Center, Icahn School of Medicine at Mount Sinai and Michigan State University...